The diagnostic benefits of SLN evaluation include an ability to identify the extent of tumor dissemination and the utility of SLN mapping in guiding targeted adjuvant treatment in high-risk patients.
The question that should be posed to those who advocate for lymphadenectomy as a tool to guide the adjuvant therapy of endometrial cancer is: At what cost to the patient is lymphadenectomy performed?
A phase I study combining the PD-L1 inhibitor durvalumab with either olaparib or cediranib found that the combinations are reasonably well tolerated and active in recurrent women’s cancers.
Patients with ovarian cancer who express the NY-ESO-1 testis antigen have significantly shorter overall survival than those who do not, according to a new study. These patients may benefit from immunotherapy agents.
How Can We Effectively Address the Medical and Psychological Concerns of Survivors of Pelvic Malignancies?
Sexual and urinary morbidities resulting from treatment of pelvic malignancies are common. Awareness of these complications is critical in order to properly counsel patients regarding potential side effects and to facilitate prompt diagnosis and management.
The use of cediranib as concurrent treatment with chemotherapy and as maintenance therapy in relapsed ovarian cancer was not associated with declines in quality of life.
The FDA announced the approval of niraparib, an oral PARP inhibitor, for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
A novel compound known as PM01183 showed promising activity in a two-stage phase II trial of women with platinum-resistant/refractory ovarian cancer.
Thromboprophylaxis with oral apixaban was similar to subcutaneous enoxaparin with regard to safety outcomes in women undergoing surgery for suspected gynecologic malignancies.
In this review we discuss preoperative diagnosis and the role of pathology, and we summarize the current literature regarding the management of uterine sarcomas.